Effectiveness of a custom anaesthetic solution on postoperative pain in hand surgery: a pilot study.

Not Applicable

• Conditions: postoperative pain management; dupuytren's disease; carpal tunnel syndrome; hand surgery; Anaesthesiology - Pain management; Surgery - Other surgery

• Registration Number: ACTRN12624000834550
• Lead Sponsor: Yi Xie - Peninsula Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-05
• Last Update Posted: 15 July 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

The study will include patients >18 years of age who will receive either open carpal tunnel release, open fasciectomy for Dupuytrens disease or both procedures in the same operation at Holmesglen Private Hospital. ; The study will include patients >18 years of age who will receive either open carpal tunnel release, open fasciectomy for Dupuytrens disease or both procedures in the same operation at Holmesglen Private Hospital.

Exclusion Criteria

Patients who are <18 years of age, have evidence of cognitive impairment as formally diagnosed by a specialist physician or neuropsychologist, or have a history of chronic pain or chronic opioid use, or are actively taking a list of prohibited anti-inflammatory medications prior to the intervention will be excluded from the study. The list of prohibited anti-inflammatory medications includes ibuprofen, naproxen, diclofenac, and celecoxib. Patients who develop any Clavien grade complication postoperatively were will also be excluded. ; Patients who are <18 years of age, have evidence of cognitive impairment as formally diagnosed by a specialist physician or neuropsychologist, or have a history of chronic pain or chronic opioid use, or are actively taking a list of prohibited anti-inflammatory medications prior to the intervention will be excluded from the study. The list of prohibited anti-inflammatory medications includes ibuprofen, naproxen, diclofenac, and celecoxib. Patients who develop any Clavien grade complication postoperatively were will also be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total opioid analgesic consumption[Total dosage of Tapentadol. This will be measured at defined follow up time points, patients will be asked to complete a VAS detailing postoperative pain, and a questionnaire outlining time to first opiate usage and total opiate usage. Tapentadol is the only analgesic assessed for this outcome, patients will be instructed not to take any other opiod analgesics or anti-inflammatories in the post-operative study period. 6 weeks postoperatively];Total opioid analgesic consumption[Total dosage of Tapentadol. This will be measured at defined follow up time points, patients will be asked to complete a VAS detailing postoperative pain, and a questionnaire outlining time to first opiate usage and total opiate usage. Tapentadol is the only analgesic assessed for this outcome, patients will be instructed not to take any other opiod analgesics or anti-inflammatories in the post-operative study period. 6 weeks postoperatively]